| Female Reproductive System Carcinoma altered in cohorts of …ALTERED_INderived200 of 680show all (up to 200) |
|---|
| ← altered in cohorts of | MYC 455 / 603 cases (75 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM135B 449 / 603 cases (74 %) · ssm · TCGA-OV · largest of 5 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 5 | Observed | gdc | graph → |
| ← altered in cohorts of | POU5F1B 449 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ACTRT3 447 / 603 cases (74 %) · ssm · TCGA-OV · largest of 2 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ADCY8 446 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AGO2 446 / 603 cases (74 %) · ssm · TCGA-OV · largest of 2 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC34 446 / 603 cases (74 %) · ssm · TCGA-OV · largest of 2 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | MYNN 446 / 603 cases (74 %) · ssm · TCGA-OV · largest of 2 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PTK2 446 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BCHE 226 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLDN16 226 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | FNDC3B 226 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPATA16 226 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TBL1XR1 226 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ZBBX 226 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | GPR20 445 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GSDMC 445 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRATD2 445 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC31 445 / 603 cases (74 %) · ssm · TCGA-OV · largest of 2 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRIQ4 445 / 603 cases (74 %) · ssm · TCGA-OV · largest of 2 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PTP4A3 445 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ASAP1 444 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CHRAC1 444 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SAMD7 444 / 603 cases (74 %) · ssm · TCGA-OV · largest of 2 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SEC62 444 / 603 cases (74 %) · ssm · TCGA-OV · largest of 2 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC45A4 444 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TG 444 / 603 cases (74 %) · ssm · TCGA-OV · largest of 6 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 6 | Observed | gdc | graph → |
| ← altered in cohorts of | TRIB1 444 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ABCC5 225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP13A5 225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | BCL6 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LPP 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | P3H2 225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PEX5L 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TP63 225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | WDR49 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | COL22A1 443 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CYRIB 443 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EPPK1 443 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPR160 443 / 603 cases (73 %) · ssm · TCGA-OV · largest of 2 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNK9 443 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KHDRBS3 443 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MECOM 443 / 603 cases (73 %) · ssm · TCGA-OV · largest of 3 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | SCRIB 443 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZFAT 443 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLDN11 442 / 603 cases (73 %) · ssm · TCGA-OV · largest of 2 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | DENND3 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM83H 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IQANK1 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MAPK15 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NRBP2 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PARP10 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PHC3 442 / 603 cases (73 %) · ssm · TCGA-OV · largest of 3 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | PRKCI 442 / 603 cases (73 %) · ssm · TCGA-OV · largest of 3 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | PUF60 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SKIL 442 / 603 cases (73 %) · ssm · TCGA-OV · largest of 3 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC7A14 442 / 603 cases (73 %) · ssm · TCGA-OV · largest of 2 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ST3GAL1 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM71 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TRAPPC9 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF623 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ABCF3 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ACTL6A 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP13A4 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ECT2 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GHSR 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IL1RAP 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | IQCG 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | MB21D2 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | MCF2L2 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NCEH1 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OPA1 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PSMD2 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLITRK3 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM207 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFSF10 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS8 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | CCDC166 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCN4 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | COL14A1 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EEF1D 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EFR3A 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GRINA 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HGH1 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MROH1 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OPLAH 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PHF20L1 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLEC 441 / 603 cases (73 %) · ssm · TCGA-OV · largest of 2 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PYCR3 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLA 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPATC1 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TIGD5 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TSNARE1 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | WASHC5 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZC3H3 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF707 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BOP1 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CYC1 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EIF5A2 440 / 603 cases (73 %) · ssm · TCGA-OV · largest of 2 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | EXOSC4 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GFUS 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPAA1 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GSDMD 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HHLA1 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNQ3 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC6 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MAFA 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MROH6 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NAPRT 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NDRG1 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NSMCE2 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OC90 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLD1 440 / 603 cases (73 %) · ssm · TCGA-OV · largest of 2 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL22L1 440 / 603 cases (73 %) · ssm · TCGA-OV · largest of 2 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SCX 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SHARPIN 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SQLE 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNIK 440 / 603 cases (73 %) · ssm · TCGA-OV · largest of 3 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | TONSL 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | WDR97 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF572 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AP2M1 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCDC39 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CHRD 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DGKG 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EIF2B5 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FGF12 223 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | GOLIM4 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HRG 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNMB2 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LIPH 223 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | MFN1 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MRPL47 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIGZ 223 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PLAAT1 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RUBCN 223 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINI2 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SOX2 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZMAT3 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF639 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADGRB1 439 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CYP11B2 439 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LY6E 439 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC2A2 439 / 603 cases (73 %) · ssm · TCGA-OV · largest of 2 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC39A4 439 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS28 439 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADIPOQ 222 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCDC50 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | CLDN1 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | DLG1 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | EEF1AKMT4-ECE2 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | EHHADH 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | EIF4G1 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | GMNC 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | HTR3C 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | HTR3D 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | HTR3E 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | KLHL24 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | KLHL6 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LRCH3 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LSG1 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | MCCC1 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | MELTF 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | NAALADL2 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PYDC2 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINI1 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM212 222 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM44 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TPRG1 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | UBXN7 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | USP13 222 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | YEATS2 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TTN 297 / 559 cases (53 %) · ssm · TCGA-UCEC · largest of 13 cohorts | — | — | Endometrial Carcinoma | 13 | Observed | gdc | graph → |
| ← altered in cohorts of | OBSCN 296 / 559 cases (53 %) · ssm · TCGA-UCEC · largest of 8 cohorts | — | — | Endometrial Carcinoma | 8 | Observed | gdc | graph → |
| ← altered in cohorts of | RYR2 291 / 559 cases (52 %) · ssm · TCGA-UCEC · largest of 11 cohorts | — | — | Endometrial Carcinoma | 11 | Observed | gdc | graph → |
| ← altered in cohorts of | ASH1L 289 / 559 cases (52 %) · ssm · TCGA-UCEC · largest of 6 cohorts | — | — | Endometrial Carcinoma | 6 | Observed | gdc | graph → |
| ← altered in cohorts of | USH2A 286 / 559 cases (51 %) · ssm · TCGA-UCEC · largest of 12 cohorts | — | — | Endometrial Carcinoma | 12 | Observed | gdc | graph → |
| ← altered in cohorts of | FLG 283 / 559 cases (51 %) · ssm · TCGA-UCEC · largest of 10 cohorts | — | — | Endometrial Carcinoma | 10 | Observed | gdc | graph → |
| ← altered in cohorts of | CACNA1E 281 / 559 cases (50 %) · ssm · TCGA-UCEC · largest of 6 cohorts | — | — | Endometrial Carcinoma | 6 | Observed | gdc | graph → |
| ← altered in cohorts of | PTEN 941 / 1,882 cases (50 %) · ssm · ucec_ancestry_cds_msk_2023 · largest of 14 cohorts | — | — | Endometrial Carcinoma | 14 | Observed | cbioportal | graph → |
| ← altered in cohorts of | HMCN1 278 / 559 cases (50 %) · ssm · TCGA-UCEC · largest of 10 cohorts | — | — | Endometrial Carcinoma | 10 | Observed | gdc | graph → |
| ← altered in cohorts of | CEP350 277 / 559 cases (50 %) · ssm · TCGA-UCEC · largest of 3 cohorts | — | — | Endometrial Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | CSMD3 277 / 559 cases (50 %) · ssm · TCGA-UCEC · largest of 10 cohorts | — | — | Endometrial Carcinoma | 10 | Observed | gdc | graph → |
| ← altered in cohorts of | HRNR 277 / 559 cases (50 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ASPM 275 / 559 cases (49 %) · ssm · TCGA-UCEC · largest of 6 cohorts | — | — | Endometrial Carcinoma | 6 | Observed | gdc | graph → |
| ← altered in cohorts of | GON4L 275 / 559 cases (49 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NFASC 271 / 559 cases (48 %) · ssm · TCGA-UCEC · largest of 4 cohorts | — | — | Endometrial Carcinoma | 4 | Observed | gdc | graph → |
| ← altered in cohorts of | CSMD1 270 / 559 cases (48 %) · ssm · TCGA-UCEC · largest of 8 cohorts | — | — | Endometrial Carcinoma | 8 | Observed | gdc | graph → |
| ← altered in cohorts of | INSRR 269 / 559 cases (48 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PDE4DIP 269 / 559 cases (48 %) · ssm · TCGA-UCEC · largest of 2 cohorts | — | — | Endometrial Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SPTA1 269 / 559 cases (48 %) · ssm · TCGA-UCEC · largest of 6 cohorts | — | — | Endometrial Carcinoma | 6 | Observed | gdc | graph → |
| ← altered in cohorts of | SETDB1 267 / 559 cases (48 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | COPA 266 / 559 cases (48 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | F5 266 / 559 cases (48 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MUC16 266 / 559 cases (48 %) · ssm · TCGA-UCEC · largest of 11 cohorts | — | — | Endometrial Carcinoma | 11 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGEF2 265 / 559 cases (47 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRRC2C 265 / 559 cases (47 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LYST 264 / 559 cases (47 %) · ssm · TCGA-UCEC · largest of 6 cohorts | — | — | Endometrial Carcinoma | 6 | Observed | gdc | graph → |
| ← altered in cohorts of | NES 264 / 559 cases (47 %) · ssm · TCGA-UCEC · largest of 2 cohorts | — | — | Endometrial Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | NUP210L 264 / 559 cases (47 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |